-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Sentinel lymph node (SN) biopsy can accurately diagnose operable oral and oropharyngeal cT1-T2N0 cancers (OC), but so far, the oncological equivalence of SN biopsy and cervical lymph node dissection (ND; standard treatment) has never been Has been evaluated
.
In this phase III multicenter trial, a total of 307 OC patients were enrolled in the study, and they were randomly assigned to (1) ND group or (2) SN group (experimental group: in the primary tumor surgery, if it is negative, it will be performed separately Biopsy, if it is positive, then proceed to ND)
.
The main result is the neck lymph node recurrence-free survival (RFS) within 2 years
As a result, a total of 279 patients (139 ND and 140 SN) data can be analyzed
.
Within 2 years, the RFS of cervical lymph nodes was 89.
In summary, this study proved the oncology equivalence of SN and ND methods.
Original source:
Renaud Garrel.
Leave a message here